MX2023012929A - Terapias de combinacion que comprenden inhibidores de shp2 e inhibidores de tirosina cinasa egfr. - Google Patents
Terapias de combinacion que comprenden inhibidores de shp2 e inhibidores de tirosina cinasa egfr.Info
- Publication number
- MX2023012929A MX2023012929A MX2023012929A MX2023012929A MX2023012929A MX 2023012929 A MX2023012929 A MX 2023012929A MX 2023012929 A MX2023012929 A MX 2023012929A MX 2023012929 A MX2023012929 A MX 2023012929A MX 2023012929 A MX2023012929 A MX 2023012929A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitors
- tyrosine kinase
- shp2
- combination therapies
- egfr tyrosine
- Prior art date
Links
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 title abstract 3
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 title abstract 3
- 229940121647 egfr inhibitor Drugs 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 238000002648 combination therapy Methods 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163184697P | 2021-05-05 | 2021-05-05 | |
| US202263320991P | 2022-03-17 | 2022-03-17 | |
| PCT/US2022/027693 WO2022235815A1 (en) | 2021-05-05 | 2022-05-04 | Combination therapies comprising shp2 inhibitors and egfr tyrosine kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023012929A true MX2023012929A (es) | 2023-11-13 |
Family
ID=83932546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023012929A MX2023012929A (es) | 2021-05-05 | 2022-05-04 | Terapias de combinacion que comprenden inhibidores de shp2 e inhibidores de tirosina cinasa egfr. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220370456A1 (https=) |
| EP (1) | EP4334317A4 (https=) |
| JP (1) | JP2024516998A (https=) |
| AU (1) | AU2022270106A1 (https=) |
| CA (1) | CA3217092A1 (https=) |
| IL (1) | IL308225A (https=) |
| MX (1) | MX2023012929A (https=) |
| WO (1) | WO2022235815A1 (https=) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017216706A1 (en) * | 2016-06-14 | 2017-12-21 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
| CA3048340A1 (en) * | 2017-01-10 | 2018-07-19 | Novartis Ag | Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor |
| CN111647000B (zh) * | 2019-03-04 | 2021-10-12 | 勤浩医药（苏州）有限公司 | 吡嗪类衍生物及其在抑制shp2中的应用 |
| US11033547B2 (en) * | 2019-03-07 | 2021-06-15 | Merck Patent Gmbh | Carboxamide-pyrimidine derivatives as SHP2 antagonists |
| JP2024505680A (ja) * | 2021-02-05 | 2024-02-07 | ベラステム・インコーポレーテッド | 異常な細胞成長を処置するための併用療法 |
| IL308222A (en) * | 2021-05-05 | 2024-01-01 | Huyabio Int Llc | Combination therapies that include SHP2 inhibitors and PD-1 inhibitors |
| JP2024516997A (ja) * | 2021-05-05 | 2024-04-18 | フヤバイオ インターナショナル，エルエルシー | Ｓｈｐ２阻害剤単独療法およびその使用 |
-
2022
- 2022-05-04 MX MX2023012929A patent/MX2023012929A/es unknown
- 2022-05-04 CA CA3217092A patent/CA3217092A1/en active Pending
- 2022-05-04 EP EP22799518.0A patent/EP4334317A4/en active Pending
- 2022-05-04 JP JP2023567923A patent/JP2024516998A/ja active Pending
- 2022-05-04 IL IL308225A patent/IL308225A/en unknown
- 2022-05-04 US US17/736,869 patent/US20220370456A1/en active Pending
- 2022-05-04 AU AU2022270106A patent/AU2022270106A1/en active Pending
- 2022-05-04 WO PCT/US2022/027693 patent/WO2022235815A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024516998A (ja) | 2024-04-18 |
| IL308225A (en) | 2024-01-01 |
| CA3217092A1 (en) | 2022-11-10 |
| WO2022235815A1 (en) | 2022-11-10 |
| EP4334317A1 (en) | 2024-03-13 |
| EP4334317A4 (en) | 2025-03-05 |
| AU2022270106A1 (en) | 2023-12-14 |
| US20220370456A1 (en) | 2022-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024000271A (es) | Inhibidor de shp2 y uso del mismo. | |
| BR112023000687A2 (pt) | Métodos e combinações de inibidores de kat6 para o tratamento de câncer | |
| CL2020003330A1 (es) | Moléculas de ácido nucleico para la reducción de arnm de papd5 o papd7 para tratar la infección por hepatitis b (divisional solicitud no. 3561-2018) | |
| BR112022009571A2 (pt) | Uso de inibidor de fak na preparação de um fármaco para tratar tumores que têm mutação nras | |
| BR112023009531A2 (pt) | Gcn2 e inibidores de perk quinase e métodos de uso dos mesmos | |
| MY209419A (en) | Protein tyrosine phosphatase inhibitors and methods of use thereof | |
| SA522441639B1 (ar) | Egfr مثبطات تفارغية وطرق استخدامها | |
| MX2021013317A (es) | Terapias de combinacion que comprenden inhibidores de apremilast y tyk2. | |
| CO2026004964A2 (es) | Moduladores de kras | |
| EA202192528A1 (ru) | Комбинация ингибиторов pd-1 и ингибиторов lag-3 для повышения эффективности при лечении рака | |
| CR20220280A (es) | Terapia de combinación que comprende un inhibidor de alk2 y un inhibidor de jak2 | |
| BR112022026186A2 (pt) | Combinação de um inibidor de bromodomínio cbp/p300 e um inibidor de kras | |
| BR112023015210A2 (pt) | Inibidores de cdk2 e métodos de uso dos mesmos | |
| BR112022022578A2 (pt) | Novas composições e métodos de tratar doença covid-19 | |
| MX2024004216A (es) | Terapias combinadas de inhibidores de kras g12d con inhibidores de la familia pan erbb. | |
| CL2023002746A1 (es) | Inhibidores de la línea 1 para tratar enfermedades del snc y sistémicas | |
| MX2024004213A (es) | Combinaciones de inhibidores de kras g12d con inhibidores de pi3ka y métodos de tratamiento relacionados. | |
| MX2024000986A (es) | Compuestos y composiciones para el tratamiento de enfermedades relacionadas con el coronavirus. | |
| MX2024012445A (es) | Terapias de combinacion que comprenden un inhibidor de sos1 y un inhibidor de egfr | |
| JOP20250150A1 (ar) | علاجات السرطان باستخدام مثبطات prmt5 التعاونية مع mta | |
| MX2024004214A (es) | Combinaciones de inhibidores de kras g12d con irinotecán y métodos de tratamiento relacionados. | |
| MX2025013118A (es) | Tratamiento combinado para una enfermedad o un trastorno relacionado con ras | |
| BR112022018948A2 (pt) | Métodos de tratamento de lesão pulmonar com inibidores de cgrp | |
| BR112023026992A2 (pt) | Medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia do medicamento em uma composição farmacêutica e método para tratar e/ou prevenir o câncer | |
| MX2021007330A (es) | Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia. |